Pipeline
Deep and Innovative Pipeline Addressing Immunological Disease
| Product Candidates | Disease Targets | Preclinical | Phase 1 | Phase 2 | Phase 3 |
|---|---|---|---|---|---|
ReproxalapDisease Targets: Dry Eye Disease Type(ophthalmic solution) | Dry Eye Disease | Preclinical | Phase 1 | Phase 2 | Phase 3 |
ReproxalapDisease Targets: Allergic Conjunctivitis Type(ophthalmic solution) | Allergic Conjunctivitis | Preclinical | Phase 1 | Phase 2 | Phase 3 |
ADX-2191Disease Targets: Proliferative Vitreoretinopathy Type(intravitreal injection) | Proliferative Vitreoretinopathy | Preclinical | Phase 1 | Phase 2 | Phase 3 |
ADX-2191Disease Targets: Primary Vitreoretinal Lymphoma Type(intravitreal injection) | Primary Vitreoretinal Lymphoma | Preclinical | Phase 1 | Phase 2 | Phase 3 |
ADX-2191Disease Targets: Retinitis Pigmentosa Type(intravitreal injection) | Retinitis Pigmentosa | Preclinical | Phase 1 | Phase 2 | Phase 3 |
RASP-Inhibitor Discovery PlatformDisease Targets: Multiple Immune-Mediated Retinal and Systemic Indications | Multiple Immune-Mediated Retinal and Systemic Indications | Preclinical | Phase 1 | Phase 2 | Phase 3 |
ADX-629Disease Targets: Autoimmune Disease (Psoriasis) Type(oral administration) | Autoimmune Disease (Psoriasis) | Preclinical | Phase 1 | Phase 2 | Phase 3 |
ADX-629Disease Targets: Cytokine Release Syndrome (COVID-19) Type(oral administration) | Cytokine Release Syndrome (COVID-19) | Preclinical | Phase 1 | Phase 2 | Phase 3 |
ADX-629Disease Targets: Allergy (Atopic Asthma) Type(oral administration) | Allergy (Atopic Asthma) | Preclinical | Phase 1 | Phase 2 | Phase 3 |